Last reviewed · How we verify
NCT04658875
Effect of Spirulina Maxima and Exercise on General Fitness and Blood Lipids in Older Adults
NA trial testing Spirulina maxima supplementation in Overweight and Obesity in 12 participants. Completed in 31 May 2024.
1 August 2022
Quick facts
| Lead sponsor | Universidad Autonoma de Baja California |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 17 January 2022 |
| Primary completion | 1 August 2022 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Spirulina maxima supplementation
- Wash-out
- Placebo supplementation
- Isoenergetic diet
- Systematic physical exercise program
Conditions studied
- Overweight and Obesity — all drugs for Overweight and Obesity →
Sponsor
Universidad Autonoma de Baja California — full company profile →
Who can join
60 and older, any sex, with Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The global older adult population has grown more than any other age group, which could be explained by the decrease of birth rate and increase of life expectancy. The healthy life expectancy of older adult in Mexico is 65.8 years, and the population's life expectancy in general is 74.4 years, this means that the population meeting that age is at increased risk of developing some disease or dependence during approximately nine years of their life. For the population over 60 years, the three most frequent health conditions reported were hypertension (40%), diabetes (24.3%), and hypercholesterolemia (20.4%). In this sense, the search for a healthy lifestyle is necessary, which includes a healthy diet that includes supplementation with nutraceuticals and the daily practice of physical activity. Regarding nutraceutical supplementation, the cyanobacterium Spirulina maxima (S. maxima) is an important source of proteins, carotenoids, phenolic compounds and polyunsaturated fatty acids which have been tested for diverse biological activities such as lipid lowering effects, however, existing studies of effects of S. maxima on body composition, physical function and blood lipid profile in humans, mainly in older adults, have a low level of evidence and absence of adequate experimental designs, so its value as a nutraceutical cannot be assured. The effects of performing systematic physical exercise in older adults have been shown to have positive effects on body composition and blood lipid profile, so in the present study it is proposed to evaluate the synergy presented by a supplement such as S. maxima in a systematic physical exercise program on the body composition, physical function and blood lipid profile of sedentary older adults with excess weight in a randomized, double-blind, crossover, placebo controlled trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of <i>Spirulina maxima</i> Intake and Exercise (SIE) on Metabolic and Fitness Parameters in Sedentary Older Adults with Excessive Body Mass: Study Protocol of a Randomized Controlled Trial.
Hernández-Lepe MA, Manríquez-Torres JJ, Ramos-Lopez O, Serrano-Medina A, et al · · 2021 · cited 1× · PMID 33567780 · DOI 10.3390/ijerph18041605
Verify or expand the search:
- PubMed search for NCT04658875
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight and Obesity
Currently open trials in the same condition.
- NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
- NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Universidad Autonoma de Baja California trials
Trials by the same sponsor.
- NCT07529652 — Psychological Intervention on Cold Executive Function and Academic Performance in University Women With Insomnia · NA · not yet recruiting
- NCT07492056 — Brain Function Messures of a Psychological Flexibility Skills Training Based on ACT Over Disordered Eating Behaviors · NA · not yet recruiting
- NCT07492069 — Life Skills-Based Intervention on Substance Use Intention in Adolescents in Social Care Institutions · NA · not yet recruiting
- NCT07492082 — Executive Functions and Emotional Intelligence in Pregnant Adolescents · NA · not yet recruiting
- NCT07184177 — Validation of Heart Rate Monitors in Overweight and Obese Young Adults · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04658875 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Autonoma de Baja California
- Last refreshed: 29 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04658875.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing